Small cell lung cancer limited stage

7 trials 3 recruiting MedDRA PT
7 Registered trials
3 Recruiting
7 Unique sponsors
6 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
L Oncology (ATC L) 3
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 2 substances
Monoclonal antibody (rat) 1 substance
PARP inhibitor 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Checkpoint inhibitor (PD-L1) 1 substance
Phase III: 3 Phase II: 3 Phase I (Other): 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

3 trials
  • Amgen Inc. Commercial
    TARLATAMAB
    2023-506235-15-00 12 countries 2024 n=145
    Recruiting
  • Merck Sharp & Dohme LLC Commercial
    OLAPARIB; PEMBROLIZUMAB
    2023-504959-27-00 11 countries 2020 n=271
    Ended
  • Shanghai Junshi Biosciences Co. Ltd. Commercial
    TIFCEMALIMAB; TORIPALIMAB
    2023-507097-41-01 8 countries 2025 n=149
    Recruiting

Phase II

3 trials
  • Fundacion GECP Academic
    TARLATAMAB
    2024-515201-26-00 1 country 2025 n=37
    Recruiting
  • Unicancer Academic
    DURVALUMAB
    2024-512224-11-00 1 country 2023 n=29
    Ended
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR Academic
    DURVALUMAB
    2024-513433-20-00 1 country 2020 n=105
    Ended

Phase I (Other)

1 trial
  • Institut De Cancerologie De L Ouest Academic
    IMP not specified
    2024-514057-30-00 1 country n=15
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amgen Inc. Commercial 1 Phase III 1
Merck Sharp & Dohme LLC Commercial 1 Phase III 0
Shanghai Junshi Biosciences Co. Ltd. Commercial 1 Phase III 1
Institut De Cancerologie De L Ouest Academic 1 Phase I (Other) 0
Fundacion GECP Academic 1 Phase II 1
Unicancer Academic 1 Phase II 0
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR Academic 1 Phase II 0
New trials by year
2020
2
2023
1
2024
1
2025
2
← All indication landscapes